Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction

Archive ouverte

Saucourt, Claire | Vogt, Sandrine | Merlin, Amandine | Valat, Christophe | Criquet, Anthony | Harmand, Laurence | Birebent, Brigitte | Rouard, Hélène | Himmelspach, Christian | Jeandidier, Éric | Chartois-Leauté, Anne-Gaële | Derenne, Sophie | Koehl, Laurence | Salem, Joe-Elie | Hulot, Jean-Sébastien | Tancredi, Céline | Aries, Anne | Judé, Sébastien | Martel, Eric | Richard, Serge | Douay, Luc | Hénon, Philippe

Edité par CCSD ; Wiley -

International audience. Abstract We previously demonstrated that intracardiac delivery of autologous peripheral blood-derived CD34+ stem cells (SCs), mobilized by granulocyte-colony stimulating factor (G-CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as Advanced Therapy Medicinal Products (ATMPs). We have industrialized their production by developing an automated device for ex vivo CD34+-SC expansion, starting from a whole blood (WB) sample. Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (a) isolation of total nuclear cells, (b) CD34+ immunoselection, (c) expansion and cell culture recovery in the device, and (d) expanded CD34+ cell immunoselection and formulation. The assessment of CD34+ cell counts, viability, and immunophenotype and sterility tests were performed as quality tests. We established graft acceptance criteria and performed validation processes in three cell therapy centers. 59.4 × 106 ± 36.8 × 106 viable CD34+ cells were reproducibly generated as the final product from 220 ml WB containing 17.1 × 106 ± 8.1 × 106 viable CD34+ cells. CD34+ identity, genetic stability, and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34+-cell categories in experimental acute myocardial infarct (AMI) in immunodeficient rats during preclinical studies. This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients. Stem Cells Translational Medicine 2019;8:822–832

Consulter en ligne

Suggestions

Du même auteur

Design and Validation of an Automated Process for the Expansion of Peripheral Blood‐Derived CD34 + Cells for Clinical Use After Myocardial Infarction

Archive ouverte | Saucourt, Claire | CCSD

International audience. We previously demonstrated that intracardiac delivery of autologous peripheral blood-derived CD34 + stem cells (SCs), mobilized by granulocyte-colony stimulating factor (G-CSF) and collected ...

Interferences of the autonomic nervous system with drug induced QT prolongation: A point to consider in non-clinical safety studies

Archive ouverte | Champeroux, Pascal | CCSD

International audience

Dietary long-chain omega-3 fatty acids of marine origin: a comparison of their protective effects on coronary heart disease and breast cancers.

Archive ouverte | Judé, Sébastien | CCSD

The relationship between high fish consumption and low mortality following coronary heart disease (CHD) and low incidence of breast cancer was first mentioned 3 decades ago. The fishes of interest are rich in omega-3 long-chain po...

Chargement des enrichissements...